

## News Releases

All Years

Search

Go

[Advanced Search](#)

**DEC 1, 2021**

**Inhibrx Receives FDA Orphan-Drug Designation for INBRX-109 in Chondrosarcoma**

**NOV 9, 2021**

**Inhibrx Reports Third Quarter 2021 Financial Results and Recent Corporate Highlights**

**NOV 3, 2021**

**Inhibrx Announces Presentations at SITC 2021**

**NOV 1, 2021**

**Inhibrx Announces Participation in Upcoming Scientific and Investor Conferences**

**OCT 28, 2021**

**Inhibrx Strengthens Leadership Team with Three Key Executive Hires and Announces Appointment of Kristiina Vuori, M.D., Ph.D. to its Board of Directors**

**SEP 13, 2021**

**Inhibrx Announces Participation in Upcoming Investor Conference**

**AUG 9, 2021**

**Inhibrx Reports Second Quarter 2021 Financial Results**

## **Inhibrx Reports Second Quarter 2021 Financial Results**

**JUN 21, 2021**

**Inhibrx Initiates a Potential Registration-Enabling Phase 2 Study of INBRX-109 in Conventional Chondrosarcoma Patients, Updates Data for Ongoing Phase 1 Study and Announces Amended Loan Agreement with Oxford**

**MAY 17, 2021**

**Inhibrx Announces Participation in Upcoming Investor Conferences**

**MAY 13, 2021**

**Inhibrx Reports First Quarter 2021 Financial Results**

**MAR 12, 2021**

**Inhibrx Reports Fourth Quarter and Fiscal Year 2020 Financial Results and Announces Phase 1 Single Agent Dose Escalation Results for INBRX-105, a Novel Targeted 4-1BB Agonist**

**FEB 1, 2021**

**Inhibrx Announces Participation in Upcoming Investor Conference**

**JAN 13, 2021**

**Inhibrx Granted Fast Track Designation for INBRX-109 for the Treatment of Unresectable or Metastatic Conventional Chondrosarcoma Patients**

**JAN 5, 2021**

**Inhibrx Announces Phase 1 Dose Escalation Results of INBRX-106, a Novel Hexavalent OX40 Agonist**

**NOV 13, 2020**

**NOV 19, 2020**

**Inhibrx Reports Financial Results for the Third Quarter 2020 and Announces Amended Loan Agreement with Oxford**

**NOV 11, 2020**

**Inhibrx Announces Positive Interim Results from the Phase 1 Trial of INBRX-109 in Chondrosarcoma Patients**

**NOV 5, 2020**

**Inhibrx Announces Participation in Upcoming Investor and Scientific Conferences**

**AUG 21, 2020**

**Inhibrx Announces Closing of Initial Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares**

**AUG 18, 2020**

**Inhibrx Announces Pricing of Initial Public Offering of Common Stock**

**JAN 8, 2020**

**Inhibrx Announces Dosing of First Patient in Phase 1 Dose-Escalation Study of INBRX-106, a Novel Hexavalent Agonist of OX40**

**SEP 3, 2019**

**Inhibrx Reports Phase 1 Dose Escalation Results of INBRX-109, a Multivalent Agonist of Death Receptor 5**

**MAY 21, 2019**

**Inhibrx Announces \$40M Investment from Viking Global Investors**

**FEB 19, 2019**

## **Inhibrx Announces Dosing of First Patient in Phase 1 Dose-Escalation Study of INBRX-105, a Novel Multispecific PD-L1 and 4-1BB Antibody**

**JAN 7, 2019**

**bluebird bio and Inhibrx Announce Collaboration to Research, Develop and Commercialize CAR T Cell Immunotherapies**

**DEC 6, 2018**

**Inhibrx Announces Dosing of First Patients in Phase 1 Dose-Escalation Study of INBRX-109, a Novel Multivalent Agonist of Death Receptor 5 (DR5)**

Show  per  
page

[«](#) [1](#) [2](#) [3](#) [4](#) [»](#)



<https://inhibrx.investorroom.com/news-releases?l=25&o=50>